Acesso livre
Acesso livre

Covid-19

[Preprint] Estudo randomizado aberto | Baricitinibe é não inferior ao tocilizumabe em pacientes internados com COVID-19 grave.

21 Jun, 2022 | 13:01h

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial – medRxiv

Conteúdos relacionados:

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

WHO recommends two new drugs to treat COVID-19 – World Health Organization

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

 

Estudo de caso controle com teste negativo | Efeitos de infecção prévia e vacinação sobre infecções sintomáticas pela variante Ômicron.

19 Jun, 2022 | 17:20h

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections – New England Journal of Medicine

Comentário: Qatar Omicron-wave study shows slow decline of natural immunity, rapid decline of vaccine immunity – Weill Cornell Medicine

Conteúdos relacionados:

Hybrid immunity: a combination of vaccination and prior infection probably offers the best protection against COVID – The Conversation

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity – Environmental Research

Two new studies show vaccination provides additional protection after Covid-19 infection.

 

Comentário no Twitter

 

Conselho do FDA é favorável às vacinas contra COVID-19 para crianças mais novas.

19 Jun, 2022 | 17:18h

FDA advisers OK COVID-19 vaccines for youngest kids – CIDRAP

Ver também: FDA advisers endorse 1st COVID-19 shots for kids under 5 – Associated Press

Perspectiva | Vírus que estiveram em pausa durante a Covid estão de volta – e se comportando de maneiras inesperadas.

19 Jun, 2022 | 16:58h

Viruses that were on hiatus during Covid are back — and behaving in unexpected ways – STAT

Estudo da Pfizer sobre o Paxlovid falha em responder a questões centrais sobre o benefício para populações mais amplas.

19 Jun, 2022 | 15:46h

Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations – STAT

Análise de eventos tromboembólicos e trombocitopênicos após vacinação contra COVID-19 com vacinas da AstraZeneca, da Pfizer e da Moderna em 3 países nórdicos.

19 Jun, 2022 | 15:40h

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries – JAMA Network Open

Estudo randomizado fase 2 | Segurança e imunogenicidade da vacina da AstraZeneca em crianças de 6-17 anos de idade.

19 Jun, 2022 | 15:37h

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial – The Lancet

Comentário convidado: Increasing children’s global access to COVID-19 vaccines – The Lancet

Revisão sistemática | Inibidores da Janus quinase para o tratamento de COVID-19.

19 Jun, 2022 | 14:38h

Janus kinase inhibitors for the treatment of COVID‐19 – Cochrane Library

Resumo: Are systemic Janus kinase inhibitors an effective treatment for people with COVID-19? – Cochrane Library

[Preprint] Estudo randomizado | Ivermectina não beneficia pacientes com COVID-19 leve a moderada no ambiente ambulatorial.

19 Jun, 2022 | 14:36h

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial – medRxiv

Comentário: Study finds no benefit to taking ivermectin for COVID-19 symptoms – Duke University

Em um estudo de doadores de sangue nos EUA, a combinação de soroprevalência do SARS-CoV-2 oriunda de infecção ou de vacinação atingiu 94,7%.

19 Jun, 2022 | 14:35h

Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021 – JAMA

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.